Determinants of Overall and Progression-Free Survival of Nigerian Patients with Philadelphia-Positive Chronic Myeloid Leukemia
Table 4
Univariate analysis of all 205 chronic phase patients’ characteristics as predictors of overall and progression-free survival.
Parameters at recruitment
Number
OS
PFS
Number
CCR
Sex: male/female
132/73
ns
0.077
65/39
ns
Age (years)
≤35/>35
70/135
0.035
ns
37/67
ns
≤40/>40
102/103
0.035
0.056
54/50
ns
≤42/>42
111/94
0.011
0.013
60/44
ns
Hematocrit at diagnosis (%)
ns
≤30/>30
76/129
0.098
0.022
37/67
ns
≤35/>35
120/85
ns
0.067
58/46
ns
WBC at diagnosis (×109/L)
ns
≤100/>100
144/128
ns
ns
61/43
ns
Platelet count (×109/L)
ns
≤250/>250
144/128
ns
ns
62/42
0.045
≤350/>350
187/85
ns
ns
ns
Time-to-imatinib (days)
>30/≤30
68/137
ns
ns
32/72
ns
>60/≤60
109/96
ns
0.083
49/55
0.083
Time-to-CHR (days)
≤30/>30
79/126
<0.001
0.002
16/88
ns
≤90/>90
125/80
0.010
0.049
50/54
ns
Spleen (cm, BCM)
Spleen: no/yes
50/155
ns
ns
23/81
ns
≤5/>5
58/147
ns
ns
28/76
ns
≤10/>10
93/112
ns
ns
48/56
ns
Liver (cm, BCM)
Liver: no/yes
140/65
ns
0.035
72/32
ns
≤5/>5
155/50
ns
ns
82/22
ns
values in bold type are significant; those in regular type are close to significance. The variables with better outcomes are written first. OS, overall survival; PFS, progression-free survival; BCM, below the costal margin; ns, not significant; NA, not applicable; CHR, complete haematologic remission; CCR, complete cytogenetic remission.
